In very elderly patients, less aggressive skin cancers on the face might not always need to be treated, a new study suggests.

Research in Review

Ipilimumab (Yervoy; Bristol-Myers Squibb) combined with local peripheral treatments such as radiotherapy or electrochemotherapy may significantly prolong survival in patients with melanoma compared with ipilimumab alone, according to a retrospective clinical study published in Cancer Immunology Research.

Read More

Discontinuing nivolumab-ipilimumab treatment because of adverse events may not have a detrimental impact on survival among patients with advanced melanoma, according to follow-up from a randomized trial presented at the American Society of Clinical Oncology Annual Meeting (June 3-7, 2016; Chicago, IL).

Read More

Subscribe to Skin Cancer